Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...
Dermatology Advisor15h
Risankizumab May Be Superior to Other Biologic Therapies in Plaque Psoriasis
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
The Healthy @Reader's Digest on MSN20h
Sunscreen vs. Sunblock: What’s the Difference?
Both sunscreen and sunblock effectively protect your skin, but dermatologists explain the pros and cons of each and which may ...